Market Overview

Morgan Stanley Sees Sapien Becoming Leading Product Line for Edwards Lifesciences

Share:
Related EW
Defense Stock Roundup: LMT-Tata Group Tie Up for F-16, HII, GD, RTN Get Big Deals from Pentagon
Why Investors Should Buy Edwards Lifesciences (EW) Right Now

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences (NYSE: EW).

In the report, Morgan Stanley noted, “Sapien should prove to be the leading product line in transcatheter valves into '14 and beyond, supported by clinical data. The TAVR market is likely to continue its expansion, supported by better budgets in Europe, favorable clinical data in lower risk populations, and more deliverable products. A mitral replacement program could drive upside given the larger potential patient pool relative to the aortic space. Higher valve revenue mix supports higher GMs.”

Edwards Lifesciences closed on Thursday at $80.27.

Latest Ratings for EW

DateFirmActionFromTo
May 2017Goldman SachsInitiates Coverage OnBuy
Feb 2017BTIG ResearchDowngradesBuyNeutral
Jan 2017GuggenheimUpgradesNeutralBuy

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!